HeartSciences Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from HeartSciences Inc.'s yearly results (2023–2026), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Cash Locked Ratio: For every $100 of sales, $7,810 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $874 tied up three years earlier. More money tied up than almost all Healthcare companies in United States.
- Tangible Net Worth Ratio: Goodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative. Less tangible than 98% of Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 3,047% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 93% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Apr 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-104.6×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 82% of Healthcare companies in United States.
Cash Locked Ratio
$7,810For every $100 of sales, $7,810 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $874 tied up three years earlier.
More money tied up than almost all Healthcare companies in United States.
Growth quality
Steadiness Ratio
1/3 · 0/3Sales grew in 1 of the last 3 years; profit grew in 0 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 16%
Sales fell 16% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-16% / +60%In 3 years sales changed by -16% while total assets changed by +60%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-2.1×Operating cash was negative last year, while some debt falls due within a year.
Higher than 63% of Healthcare companies in United States.
Cash Cushion Ratio
−15%Debt, after subtracting cash, equals 15% of its market value (net debt).
Lower than 82% of Healthcare companies in United States.
Tangible Assets Ratio
55%Of every $100 the company owns, $55 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 74% of Healthcare companies in United States.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than 98% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
HeartSciences Inc. made a loss over the last year. HeartSciences Inc. owes $1.54 for every $1 it owns. HeartSciences Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Apr 2026.
P/E ratio
LossHeartSciences Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-7.55HeartSciences Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$15 MThe total market value of all of HeartSciences Inc.'s shares at today's price (share price × number of shares), smaller than 84% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
NegativeHeartSciences Inc.'s net worth is negative ($2 M below zero, balance sheet 31 Jul 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Return on equity (ROE)
-1851.9%HeartSciences Inc. lost 1851.9% of its shareholders' money over the last year, lower than almost all Healthcare companies in United States.
Owes vs Owns
1.54×HeartSciences Inc. owes $1.54 for every $1 it owns, so it owes more than it owns, higher than 94% of Healthcare companies in United States.
Dividend yield
NoneHeartSciences Inc. does not currently pay a dividend.
Revenue growth
-1%Revenue fell 1% in the year to Apr 2026, and shrank 6% a year on average over 3 years.
Profit growth
LossHeartSciences Inc. made a loss in each of the last two years.
Profit margin
-211666.5%HeartSciences Inc. lost $211666 for every $100 of revenue.
Interest cover
Not coveredHeartSciences Inc.'s operating profit did not cover its interest costs in the year to Apr 2026.
Cash vs debt
Net debtHeartSciences Inc. had $2 M more debt than cash (net debt) at Apr 2026.
Questions
What is HeartSciences Inc.'s return on equity?
HeartSciences Inc. lost 1851.9% of its shareholders' money over the last year, lower than almost all Healthcare companies in United States.
How much does HeartSciences Inc. owe compared with what it owns?
HeartSciences Inc. owes $1.54 for every $1 it owns, so it owes more than it owns, higher than 94% of Healthcare companies in United States.
Does HeartSciences Inc. pay a dividend?
No. HeartSciences Inc. does not currently pay a dividend.
Is HeartSciences Inc.'s revenue growing?
Revenue fell 1% in the year to Apr 2026, and shrank 6% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.